Halda Therapeutics Announces $126M Funding for Cancer Treatment Innovations
Monday, 12 August 2024, 11:55
Halda Therapeutics' Major Funding Round
Halda Therapeutics has raised $126 million to fund its innovative cancer treatment development.
Focus on Drug Resistance
- RIPTAC therapeutics targeting metastatic castration-resistant prostate cancer
- Initial clinical trial planned for 2025
This funding aims to tackle the pressing issue of drug resistance in cancer therapies.
Conclusion
With this financial boost, Halda Therapeutics is well-positioned to advance its clinical trials, potentially transforming the landscape of cancer treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.